Dermacyn Wound regulatory update

Oculus said the British Standards Institution (BSI) and the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved CE Mark reclassification of its Dermacyn wound care product to a Class III medical device from a Class IIB device. The product is for use in the debridement, irrigation and moistening of acute and chronic wounds, ulcers, cuts, abrasions and burns. The active substances in the product were also classified as having an antimicrobial effect. ...